182 related articles for article (PubMed ID: 10103195)
21. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).
Jones RN; Stilwell MG; Rhomberg PR; Sader HS
Diagn Microbiol Infect Dis; 2009 Nov; 65(3):331-4. PubMed ID: 19822273
[TBL] [Abstract][Full Text] [Related]
22. In vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity.
Muñoz Bellido JL; Muñoz Criado S; García García I; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; García-Rodríguez JA
Antimicrob Agents Chemother; 1997 Dec; 41(12):2612-5. PubMed ID: 9420028
[TBL] [Abstract][Full Text] [Related]
23. Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Dec; 38(12):2905-7. PubMed ID: 7695281
[TBL] [Abstract][Full Text] [Related]
24. Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli.
Pohlman JK; Knapp CC; Ludwig MD; Washington JA
Diagn Microbiol Infect Dis; 1996 Sep; 26(1):29-33. PubMed ID: 8950526
[TBL] [Abstract][Full Text] [Related]
25. Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.
Van der Auwera P; Duchateau V; Lambert C; Husson M; Kinzig M; Sörgel F
Antimicrob Agents Chemother; 1993 Sep; 37(9):1860-8. PubMed ID: 8239597
[TBL] [Abstract][Full Text] [Related]
26. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.
Jacobs MR; Aronoff SC; Johenning S; Yamabe S
J Antimicrob Chemother; 1986 Aug; 18(2):177-84. PubMed ID: 3019984
[TBL] [Abstract][Full Text] [Related]
27. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
Burgess DS; Waldrep T
Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.
Lyon MD; Smith KR; Saag MS; Cloud GA; Cobbs CG
Antimicrob Agents Chemother; 1986 Jul; 30(1):25-30. PubMed ID: 3092731
[TBL] [Abstract][Full Text] [Related]
30. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Burgess DS; Hastings RW
Diagn Microbiol Infect Dis; 2000 Sep; 38(1):37-41. PubMed ID: 11025182
[TBL] [Abstract][Full Text] [Related]
31. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
Hou F; Li J; Gao L; Chen Y
Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of piperacillin/tazobactam against recent clinical isolates from hospitalized patients in ten Belgian hospitals.
Verbist L; Dhoore P
Acta Clin Belg; 1995; 50(5):274-81. PubMed ID: 8533527
[TBL] [Abstract][Full Text] [Related]
33. Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis.
Hoellman DB; Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Apr; 42(4):857-61. PubMed ID: 9559796
[TBL] [Abstract][Full Text] [Related]
34. [Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].
Sacha PT; Jakoniuk P; Wieczorek P; Zalewska M; Leszczyńska K
Med Dosw Mikrobiol; 2004; 56(3):263-73. PubMed ID: 15773503
[TBL] [Abstract][Full Text] [Related]
35. Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas.
WaKabongo M; Stucki ZN; Torbert DP; Olweny J
J Am Osteopath Assoc; 2005 Jan; 105(1):25-6. PubMed ID: 15710671
[No Abstract] [Full Text] [Related]
36. Clavulanic acid in combination with ticarcillin: an in-vitro comparison with other beta-lactams.
Clarke AM; Zemcov SJ
J Antimicrob Chemother; 1984 Feb; 13(2):121-8. PubMed ID: 6323375
[TBL] [Abstract][Full Text] [Related]
37. [Chemical structure, anti-bacterial activity and pharmacokinetics of penicillins].
Miyashita T; Ono Y; Kunii O
Nihon Rinsho; 1991 Oct; 49(10):2266-70. PubMed ID: 1660944
[No Abstract] [Full Text] [Related]
38. [Comparative activity of ticarcillin-clavulanic acid and various beta-lactams against Pseudomonas maltophilia].
Monteil H; Jehl F
Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):805-8. PubMed ID: 3309818
[TBL] [Abstract][Full Text] [Related]
39. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Raveh D; Yinnon AM; Broide E; Rudensky B
Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
[TBL] [Abstract][Full Text] [Related]
40. [In vitro study of the effects of a ticarcillin-clavulanic acid combination on Pseudomonas aeruginosa as a function of resistant phenotypes].
Thabaut A; Meyran M
Pathol Biol (Paris); 1985 May; 33(5):408-11. PubMed ID: 3929218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
